Parkwalk invested in Mode Diagnostics (Mode Dx) in May 2012. In Q1 2016 the company was voluntarily struck-off and its assets were sold for a nominal sum.
Mode Dx was a development company focused on integrating biosensing and electronics to produce products for the home-based point-of-care markets.
Mode was looking to exploit the electrochemical properties of biomarkers to produce novel assays for home diagnostic purposes. Mode’s proprietary platform – Measure – was a flexible, low-cost and hygienic platform that could easily be configured to create health tests for both the Physician’s Office and Consumer self-testing.
Mode’s first product – Measure Bowel Health – represented an evolution in bowel cancer screening that offered significant improvements over the then current testing methods.